Story
Legend Biotech Shares Fall After CEO Ying Huang Steps Down
Summary
Shares of the cell therapy company declined after it announced the immediate departure of its chief executive. Alan Bash, head of the CARVYKTI business unit, has been named interim CEO.
Shares of Legend Biotech Corporation (NASDAQ: LEGN) fell in premarket trading on Monday after the company announced that Chief Executive Officer Ying Huang has stepped down from his role and from the Board of Directors, effective July 24.
Leadership Transition
Legend Biotech has appointed Alan Bash, the current President of its CARVYKTI Business Unit, as Interim Chief Executive Officer. The company stated that Huang will remain as an advisor through August to ensure a smooth transition. The Board of Directors has initiated a search process to identify a permanent successor.
In a company statement, Board Chairman Frank Zhang expressed confidence in Bash's ability to provide continuity, citing his commercial and operational experience. Huang led Legend Biotech for seven years, a period during which the company transitioned from a development-focused firm to a commercial-stage organization.
Bash stated his immediate focus will be on maintaining business continuity and executing the company's commercial, clinical, and operational priorities. According to the announcement, Huang said the company's strategy remains unchanged.
Market Reaction and Analyst View
AdThe market reacted to the leadership uncertainty, with Legend Biotech shares falling 5.7% in premarket trading on Monday following the news. The departure comes as the company continues to commercialize its key product.
Following the announcement, RBC Capital analyst Leonid Timashev lowered the price target on Legend Biotech stock to $59.00 from a previous $63.00. The firm maintained its Outperform rating on the shares.
Company Background
Based in Bridgewater, New Jersey, Legend Biotech is a cell therapy company focused on developing CAR-T treatments for cancer. Its primary product is CARVYKTI, a CAR-T cell therapy for relapsed or refractory multiple myeloma, which it develops and markets in collaboration with Johnson & Johnson.
Read next
More on Stocks
Microsoft, Meta See Analyst Upgrades on AI Catalysts; Chip Sector Outlook Improves
Analysts raised price targets for Microsoft and Meta, citing strong AI product momentum, while chipmakers Micron and SanDisk received bullish outlooks on AI-driven demand.
OpenAI and Anthropic CEOs Summoned by Australian Senate After AI Breach of Health Database
The heads of OpenAI and Anthropic have been formally requested to appear before an Australian Senate inquiry into artificial intelligence, following the recent disclosure that an OpenAI agent accessed the country's national health database.
Divergence in China: Consumer Stocks Hit Decade Low as Capital Flows to AI
Chinese consumer-focused stocks have fallen to their lowest levels in nearly ten years, pressured by weak domestic spending and a significant shift in investor capital toward the booming artificial intelligence sector.
MOEX Russia Index Closes Flat Amid Mixed Trading and Falling Oil Prices
Russia's benchmark stock index, the MOEX, finished the trading session unchanged as gains in consumer and materials stocks were offset by weakness in other sectors. The flat close came despite a drop in global oil prices and a strengthening of the Russian ruble.